Glofitamab for Lymphoma

Recruiting in Palo Alto (17 mi)

Overseen by Dai Chihara, M D

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The goal of this clinical research study is to learn if glofitamab can help to prevent recurrence of LBCL in patients who have achieved CR after standard first-line therapy but have tested positive for MRD. The safety of glofitamab will also be studied.

Research Team

Dai Chihara, M D

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

Adults over 18 with certain types of large B-cell lymphoma who've had a complete response to first-line therapy but still have minimal residual disease (MRD). They must be in good health, understand the study, and agree to use contraception. Excluded are those with significant heart issues, recent surgeries or transfusions, other cancers within 3 years, severe allergies to therapies, immune conditions or treatments that could interfere.

Inclusion Criteria

I am 18 years old or older.

My cancer responded completely to the first treatment according to Lugano criteria.

Understand and sign a written informed consent document

Exclusion Criteria

I have a serious heart condition.

I have not had a recent blood transfusion or taken any experimental drugs.

I have had surgery recently.

Treatment Details

Interventions

• Glofitamab (Monoclonal Antibodies)

Trial Overview The trial is testing Glofitamab's effectiveness in preventing the return of large B-cell lymphoma after initial successful treatment. Participants must have achieved complete remission but show MRD presence. The safety profile of Glofitamab will also be evaluated during this phase.

Participant Groups

Group I: Glofitamab Experimental Treatment 1 Intervention

Participants will enter a screening period to determine eligibility for the study

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

The University of Texas M. D. Anderson Cancer Center Houston, TX

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3107

Recruited

1,813,000+

Peter WT Pisters

M.D. Anderson Cancer Center

President since 2017

MD from the University of Western Ontario, residency at the University of Toronto, fellowship at the University of Texas MD Anderson Cancer Center

Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Executive

MD from Stanford University School of Medicine, surgical training and research fellowship in tumor immunology at Stanford

Genentech, Inc.

Industry Sponsor

Trials

1578

Recruited

569,000+

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

Bachelor's degree from Princeton University, MBA from Harvard University

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2019

M.D. and Ph.D. from Harvard University